Current State-of-Art of Extracellular Vesicles for Targeting Gene Therapy in Neurological Disorders
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 3549
Special Issue Editors
Interests: non-viral vectors; gene delivery; neurological diseases; extracellular vesicles; translational research
Interests: neurobiology; neuroscience; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Extracellular vesicles (EVs) are achieving considerable accomplishments in targeted gene therapy, opening a new frontier to develop gene delivery strategies for neurological disorders. In addition to the cargo of different proteins, lipids, and nucleic acid, EVs isolated from patients diagnosed with Alzheimer’s and Parkinson’s disease and recently also multiple sclerosis show an altered genetic cargo in the form of miRNA. This has boosted the EVs’ role as biomarkers in the diagnosis of human neurological diseases. However, so far, most EVs studies have been performed using in vitro and in vivo models. Standardization of methodologies and testing across human neurodisorders still represent key challenges. This Special Issue aims to harvest the latest advanced studies of EVs in diagnosing and treating central nervous system diseases, sharing knowledge and data with readers and scientists working in this discipline to foster an effective and safe clinical translation of these unique intercellular delivery vehicles.
Dr. Nicola Orefice
Prof. Markus Kipp
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-viral vectors
- gene delivery
- neurological diseases
- extracellular vesicles
- translational research
